Early study paves way for new heart disease treatment
NCT ID NCT07677163
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage trial studies how different tablet forms of MK-1403, a drug designed for heart and blood vessel disease, are absorbed and tolerated in healthy adults. Researchers will measure the drug levels in the blood and monitor for any side effects. The results will help decide which formulation to use in future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MK-1403
- What this could lead to
- If successful, this study could help select the best formulation of MK-1403 for future trials in people with heart disease.
- What could go wrong
- This is a very early, small study in healthy people, not patients. The drug may not work as hoped in later trials or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test